vimarsana.com

Alanj Kivitz News Today : Breaking News, Live Updates & Top Stories | Vimarsana

IV Secukinumab Trials Hit Primary Endpoints in PsA, AxSpA

Alan J Kivitz, MD: Phase 2b Data on TAK-279 for Psoriatic Arthritis

During this interview, Dr. Kivitz explained the background and key findings of his team’s research on TAK-279, a selective oral TYK2 inhibitor.

Alan J Kivitz, MD: Next Steps for Research on TAK-279 for Psoriatic Arthritis

This segment of Dr. Kivitz’s interview at ACR 2023 featured a discussion about future research on TAK-279 as well as general outlook on the field for psoriatic arthritis.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.